M2 Archive: Preview
You haven't logged in. If you have archive credits in your account, please log in now to use them. If not, you can buy credits in our shopping area.
LEO Pharma reports positive phase 2b results for temtokibart in atopic dermatitis
Danish pharmaceutical company LEO Pharma A/S on Friday announced positive topline results from its phase 2b clinical trial of temtokibart (LEO 138559), an investigational IL-22RA1 antagonist for moderate-to-severe atopic dermatitis.
The randomised, double-blind, placebo-controlled trial...
If you want to view the full text of this story, you must first purchase archive credits. Return to Archives
New Search